“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes ...

“The majority (76%) of patients not yet meeting the Phoenix criteria did have PSMA-avid lesions on PSMA-PET, suggesting [prostate cancer] recurrence," says Evelien J E van Altena.

“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.

The TENACIO Pump's smaller design and pronounced decompression mechanism improve patient interaction with the implant. Helen L. Bernie reports no challenges in implanting the AMS 700 with TENACIO Pump ...

In this video, Kara Cossis, PA-C, MPH, discusses the role of advanced practice providers (APPs) in expanding and encouraging the use of genetic testing for prostate cancer. Cossis is a physician ...

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, ...

Tailor the program to available resources and staff, ensuring it fits the specific practice environment. Consistent patient-provider interactions enhance patient experience, though not always possible ...

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD. In this video, ...

Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.

Enzalutamide plus GnRH significantly improved metastasis-free survival in nmCSPC patients with high BCR risk compared to monotherapies. The study population included patients with PSA doubling time ≤ ...

Darolutamide plus ADT significantly improved radiological progression-free survival and overall survival in mHSPC patients compared to placebo. The ARANOTE trial demonstrated benefits in secondary ...

Katie S. Murray, DO, provides an overview of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), defining it as a form of bladder cancer that does not respond to BCG therapy and explaining ...